Related Experiment Video
Updated: Jul 12, 2025
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-Cell Lymphoma, Leg-Type: A Case Report
Sabrina Zoli1,2, Cinzia Pellegrini1, Beatrice Casadei1
1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Lenalidomide monotherapy achieved a durable complete remission in a relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT) patient. This offers a promising treatment option for refractory PCDLBCL-LT.
Area of Science:
- Hematology
- Oncology
- Dermatology
Background:
- Primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT) lacks standardized second-line treatment protocols for relapsed cases.
- Relapsed or refractory PCDLBCL-LT presents a significant clinical challenge.
Observation:
- A case study involving an elderly patient with relapsed/refractory PCDLBCL-LT is presented.
- The patient received lenalidomide as a single-agent therapy.
Findings:
- Lenalidomide monotherapy resulted in an extended clinical complete remission.
- The treatment exhibited manageable toxicity profiles.
Implications:
- Lenalidomide demonstrates potential as an effective salvage therapy for PCDLBCL-LT.
- Further investigation into lenalidomide for PCDLBCL-LT is warranted to establish its role in treatment guidelines.
More Related Videos
15:07VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
Published on: December 28, 2015
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017